Funding Opportunity RFA-CA-23-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (NOFO) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Notice NOT-CA-23-061 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-008 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-118 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-059 from the NIH Guide for Grants and Contracts

Notice NOT-RM-23-012 from the NIH Guide for Grants and Contracts

Notice NOT-RM-23-011 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-109 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-111 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-115 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-24-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria.This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

Funding Opportunity PAR-23-150 from the NIH Guide for Grants and Contracts. The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-18-NNN).

Funding Opportunity PAR-23-149 from the NIH Guide for Grants and Contracts. The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PA-18-NNN ).

Funding Opportunity RFA-CA-23-029 from the NIH Guide for Grants and Contracts. The purpose of the Cancer Immunoprevention Network (CIP-Net) is to support a deeper understanding of basic mechanisms of immunoprevention, discover novel immunoprevention strategies, and foster a community of cancer immunoprevention researchers. ?The UG3/UH3 research projects will enable de novo discovery of immune pathways, immunoprevention mechanisms, or investigation of new vaccine or immunomodulatory targets or agents. Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Achievement of the UG3 milestones will be necessary for transition to the UH3 phase. UH3 phase may be awarded after administrative review of the UG3 milestones. Provided these milestones are achieved, UH3 phase may continue.

Notice NOT-HG-23-037 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-117 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-021 from the NIH Guide for Grants and Contracts

Notice NOT-AI-23-042 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-23-026 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance synthetic nucleic acid platforms for the rapid development and iterative testing of active and passive immunization strategies for HIV prevention, treatment, and cure. This funding opportunity will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones.

Notice NOT-AR-23-019 from the NIH Guide for Grants and Contracts